Source-grounded facts extracted from Liquidia Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Liquidia Corp shareholders approved Approval, by non-binding advisory vote, of the compensation of the Company's named executive officers at the 2026-06-16 meeting.
“The vote with respect to the approval, by non-binding advisory vote, of the compensation of the NEOs was as follows: For Against Abstain Broker Non-Votes 44,270,299 612,749 49,530 22,546,609”
Liquidia Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-16 meeting.
“The vote with respect to the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was as follows: For Against Abstain 67,279,878 183,739 15,570”
Liquidia Corp shareholders approved Election of three Class II directors to serve until the Company's 2029 Annual Meeting of Stockholders at the 2026-06-16 meeting.
“The vote with respect to the election of Class II directors was as follows: Nominees For Withheld Broker Non- Votes Katie Rielly-Gauvin 41,448,383 3,484,195 22,546,609 Ramandeep Singh 41,158,353 3,774,225 22,546,609 David Johnson 44,874,399 58,179 22,546,609”
Liquidia Corp reported first quarter ended March 31, 2026 results: revenue $129.9 million, net income $52.9 million, EPS $0.60 per basic and $0.52 per diluted share.
“First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.”
Liquidia Corp reported fourth quarter of 2025 results: revenue $90.1 million, net income net income of $14.6 million.
“Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update · Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter · More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 · Ended 2025 with $190.7 million in cash and”
Liquidia Corp reported the year ended December 31, 2025 results: revenue $148.3 million, net income net loss of $68.9 million, EPS $0.80 per basic and diluted share.
“99.1 Exhibit 99.1 Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update · Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter · More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 ·”
Liquidia Corp reported full year ended December 31, 2023 results: revenue $17.5 million.
“$25.0 million. HCRx has now invested $67.5 million in non-dilutive capital from the $100 million originally contemplated from four tranches under the RIFA. Revenue was $17.5 million for the year ended December 31, 2023, compared with $15.9 million for the year ended December 31, 2022. Revenue related primarily to the sale of Treprostinil Injection under the”
Michael Kaseta changed role as Chief Operating Officer at Liquidia Corp.
“On January 15, 2024 (the “Effective Date”), the Company promoted Michael Kaseta, the current Chief Financial Officer (“CFO”) of the Company, to the role of Chief Operating Officer (the “COO”), effective immediately.”
Robert Lippe was terminated as Chief Operations Officer at Liquidia Corp.
“On January 15, 2024, Liquidia Corporation, a Delaware corporation (the “Company”) terminated Robert Lippe from his position as the Chief Operations Officer of the Company.”
Liquidia Corp entered into Registration Rights Agreement with Legend Aggregator, LP valued at Agreement to file registration statement for resale of Private Placement Shares (effective 2024-01-04).
“In connection with the Private Placement, on January 4, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchaser.”
Liquidia Corp entered into Fourth Amendment to Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. valued at $25,000,000 additional funding (effective 2024-01-03).
“On January 3, 2024, Liquidia Technologies and HCR entered into a Fourth Amendment to the Financing Agreement (the “Fourth Amendment”) to fund an additional $25.0 million thereunder.”
Liquidia Corp entered into Common Stock Purchase Agreement with Roger Jeffs valued at Private sale of 139,665 unregistered shares of common stock at $7.16 per share, aggregate investment (effective 2023-12-12).
“Concurrently with the Offering referenced above, on December 12, 2023, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Roger Jeffs, the Chief Executive Officer of the Company, in connection with the private sale of 139,665 unregistered shares (the “Private Shares” and together with the Public Shares, the “Shares”) of the Company’s Common Stock, in a private placement at a purchase price of $7.16 per share for an aggregate investment amount of approximately $1 million (the “Private Placement”).”
Liquidia Corp entered into Underwriting Agreement with BofA Securities, Inc. valued at Sale of 3,491,620 shares of common stock at $7.16 per share, gross proceeds approximately $25 millio (effective 2023-12-12).
“On December 12, 2023, Liquidia Corporation, a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc. (“ Representative ”), as representative of the several underwriters named therein (collectively, the “Underwriters”), in connection with a sale of 3,491,620 shares (the “Public Shares”) of the Company’s common stock, par value $0.001 per share ( the “Common Stock), pursuant to a registration statement on Form S-3 (File No. 333-251394), filed with the United States Securities and Exchange Commission (the “SEC”) on December 16, 2020, and which was declared effective by the SEC on December 23, 2020, and the prospectus contained therein, as may be supplemented by a prospectus supplement (the “Prospectus Supplement ”) to be filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act ”), in an underwritten registered public offering (the “Offering”) at an offering p”
Liquidia Corp reported the third quarter ended September 30, 2023 results: revenue $3.7 million.
“for PAH and PH-ILD. Third Quarter 2023 Financial Results Cash totaled $76.2 million as of September 30, 2023, compared to $93.3 million as of December 31, 2022. Revenue was $3.7 million for the three months ended September 30, 2023, compared to $3.2 million for the three months ended September 30, 2022. Revenue related primarily to the promotion agreement”
Liquidia Corp reported second quarter ended June 30, 2023 results: revenue $4.8 million, net income $23.5 million, EPS $0.36 per basic and diluted share.
“of PH-LD patients with L606. Second Quarter 2023 Financial Results Cash totaled $88.2 million as of June 30, 2023, compared to $93.3 million as of December 31, 2022. Revenue was $4.8 million for the three months ended June 30, 2023, compared to $3.9 million for the three months ended June 30, 2022. Revenue related primarily to the promotion agreement between Liquidia”
Liquidia Corp amended Third Amendment to the Financing Agreement with HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC (collectively, “HCR”) valued at $10 million second tranche (effective 2023-07-27).
“On July 27, 2023, Liquidia Technologies and HCR entered into a Third Amendment to the Financing Agreement (the “Third Amendment”), pursuant to which, among other things, (i) HCR agreed to make payment of the $10 million second tranche under the Financing Agreement on July 27, 2023”
Liquidia Corp amended Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC f/k/a Xcelience LLC (effective 2023-07-14).
“On July 14, 2023, Liquidia Corporation, a Delaware corporation through Liquidia Technologies, Inc., a Delaware corporation (the “Company”) and wholly owned subsidiary of Liquidia Corporation, entered into an Amended and Restated Commercial Manufacturing Services and Supply Agreement (the “Agreement”) with Lonza Tampa LLC f/k/a Xcelience LLC (“Lonza”).”
Liquidia Corp amended Second Amendment to Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. and HealthCare Royalty Management, LLC valued at Amendment moves $2.5 million from fourth tranche to second tranche, resulting in $10 million total s (effective 2023-06-28).
“On June 28, 2023, Liquidia Technologies and HCR entered into a Second Amendment to the Financing Agreement (the “Second Amendment”), pursuant to which, HCR will move $2.5 million from the fourth tranche to the second tranche under the Financing Agreement. As a result, HCR will fund a total of $10 million (as the second tranche under the Financing Agreement), which will be used for the upfront payment owed to Pharmosa in connection with the transactions contemplated by the License Agreement.”
Liquidia Corp entered into License Agreement with Pharmosa Biopharm Inc. valued at Upfront payment of $10 million; potential development milestone payments up to $30 million; potentia (effective 2023-06-28).
“License Agreement with Pharmosa Biopharm On June 28, 2023, Liquidia Technologies, Inc., a Delaware corporation (the “Liquidia Technologies”) and a wholly owned subsidiary of Liquidia Corporation”
Liquidia Corp shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-15 meeting.
“The vote with respect to the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 was as follows: For Against Abstain 53,649,528 27,365 319,819”
Liquidia Corp shareholders approved Approval of an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 80,000,000 to 100,000,000 at the 2023-06-15 meeting.
“The vote with respect to the approval of the Charter amendment was as follows: For Against Abstain 50,702,381 2,265,108 1,029,223”
Liquidia Corp shareholders approved Election of three Class II directors to serve until the 2026 Annual Meeting at the 2023-06-15 meeting.
“The vote with respect to the election of Class II directors was as follows: Nominees For Withheld Broker Non- Votes Katherine Rielly-Gauvin 28,102,084 4,538,363 21,356,265 Raman Singh 27,831,024 4,809,423 21,356,265 David Johnson 26,229,870 6,410,577 21,356,265”
Liquidia Corp entered into Supply Agreement with Plastiape SpA (effective 2023-06-07).
“On June 7, 2023, Liquidia Corporation, a Delaware corporation through Liquidia Technologies, Inc., a Delaware corporation (the “Company”) and wholly owned subsidiary of Liquidia Corporation, entered into a Supply Agreement (the “Agreement”) with Plastiape SpA, a company organized and existing under the laws of Italy (“Plastiape”).”
Liquidia Corp reported Q1 2023 results: revenue $4.5 million, net income -$11.7 million, EPS -$0.18.
“Revenue was $4.5 million for the three months ended March 31, 2023, compared to $3.5 million for the three months ended March 31, 2022. Revenue related primarily to the Promotion Agreement. The increase of $1.0 million was primarily due to increased quantities and favorable gross-to-net rebate adjustments. Cost of revenue was $0.7 million for both the three months ended March 31, 2023 and 2022. Cost of revenue related to the Promotion Agreement as noted above. Research and development expenses were $5.3 million for the three months ended March 31, 2023, compared with $4.7 million for the three months ended March 31, 2022. The increase of $0.6 million or 12% was primarily due to a $0.5 million increase in consulting and personnel expenses in preparation for the potential commercialization of YUTREPIA. General and administrative expenses were $7.8 million for the three months ended March 31, 2023, compared with $12.5 million for the three months ended March 31, 2022. The decrease of $4.7”
Liquidia Corp terminated Inhalation Collaboration and Option Agreement with Glaxo Group Limited (GSK) (effective 2023-03-31).
“The Agreement supersedes and replaces that certain Inhalation Collaboration and Option Agreement, dated as of June 15, 2012, by and between Liquidia Technologies and GSK, as amended on May 13, 2015, November 19, 2015 and June 24, 2019 (the “Prior Agreement”).”
Liquidia Corp entered into Research License Agreement with Glaxo Group Limited (GSK) (effective 2023-03-31).
“On March 31, 2023, Liquidia Corporation, a Delaware corporation (the “Company”) through Liquidia Technologies, Inc., a Delaware corporation (“Liquidia Technologies”) and wholly owned subsidiary of the Company, entered into a Research License Agreement (the “Agreement”) with Glaxo Group Limited, a company organized and existing under the laws of England (“GSK”).”
Liquidia Corp reported financial results for full year ended December 31, 2022.
“issued a press release announcing its financial results for the full year ended December 31, 2022, and also provided a corporate update.”
Liquidia Corp amended Fourth Amendment to Promotion Agreement with Sandoz Inc. (effective 2023-03-10).
“On March 10, 2023, Liquidia PAH, LLC, a Delaware limited liability company (formerly known as RareGen, LLC) (“Liquidia PAH”) and wholly-owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into a Fourth Amendment to Promotion Agreement (the “Fourth Amendment”) with Sandoz Inc. (“Sandoz”).”
Liquidia Corp terminated Amended and Restated Loan and Security Agreement with Silicon Valley Bank valued at payoff amount of $22,356,635 (effective 2023-01-27).
“On the Initial Closing Date, the SVB Loan was terminated upon the receipt by SVB of a payoff amount of $22,356,635 from the Company Group.”
Liquidia Corp incurred debt of $32.5 million of the Investment Amount will be funded at the initial closing with HealthCare Royalty Partners IV, L.P. at tiered royalty on annual net revenue ... ranging from 3.60% to 10.00% on the fir.
“ntered into a Revenue Interest Financing Agreement (the “Agreement”) with HealthCare Royalty Partners IV, L.P. (the “Investor”) and HealthCare Royalty Management, LLC.”
Liquidia Corp entered into Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. valued at up to $100.0 million (effective 2023-01-09).
“On January 9, 2023, Liquidia Technologies, Inc., a Delaware corporation (the “Company”) and a wholly owned subsidiary of Liquidia Corporation (the “Parent”) entered into a Revenue Interest Financing Agreement (the “Agreement”) with HealthCare Royalty Partners IV, L.P. (the “Investor”) and HealthCare Royalty Management, LLC. Pursuant to the Agreement and subject to customary closing conditions, the Investor has agreed to pay the Company an aggregate investment amount of up to $100.0 million (the “Investment Amount”).”
Liquidia Corp entered into Pump Development Agreement with Mainbridge Health Partners, LLC and Sandoz Inc. (effective 2022-12-01).
“On December 1, 2022, Liquidia PAH, LLC, a Delaware limited liability company (“Liquidia PAH”), a wholly-owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into a Device Development and Supply Agreement (the “Pump Development Agreement”) with Mainbridge Health Partners, LLC (“Mainbridge”) and Sandoz Inc. (“Sandoz”).”
Liquidia Corp amended Third Amendment to Promotion Agreement with Sandoz Inc. (effective 2022-11-18).
“On November 18, 2022, Liquidia PAH, LLC, a Delaware limited liability company (formerly known as RareGen, LLC) (“Liquidia PAH”) and wholly-owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into a Third Amendment to Promotion Agreement (the “Third Amendment”) with Sandoz Inc. (“Sandoz”).”
Liquidia Corp reported third quarter ended September 30, 2022 results: revenue $3.2 million.
“or dropping the device. Third Quarter 2022 Financial Results Cash totaled $98.3 million as of September 30, 2022, compared to $57.5 million as of December 31, 2021. Revenue was $3.2 million for the three months ended September 30, 2022, compared to $3.2 million for the three months ended September 30, 2021. Revenue related primarily to the Promotion Agreement.”
Tushar Shah was terminated as Chief Medical Officer at Liquidia Corp.
“As previously disclosed, effective June 15, 2022 (the “Separation Date”), Tushar Shah, M.D.’s employment with Liquidia Corporation, a Delaware corporation (the “Company”) as the Company’s Chief Medical Officer terminated.”
Tushar Shah was terminated as Chief Medical Officer at Liquidia Corp.
“Effective June 15, 2022, Tushar Shah, M.D.’s employment with Liquidia Corporation, a Delaware corporation (the “Company”) as the Company’s Chief Medical Officer terminated.”
Roger A. Jeffs, Ph.D. was appointed as Chief Executive Officer at Liquidia Corp.
“Damian deGoa, the former Chief Executive Officer and a current Class III director of Liquidia Corporation, a Delaware corporation (the “Company”), resigned from his position as Chief Executive Officer of the Company and was succeeded by Roger A. Jeffs, Ph.D.”
Damian deGoa resigned as Chief Executive Officer at Liquidia Corp.
“Damian deGoa, the former Chief Executive Officer and a current Class III director of Liquidia Corporation, a Delaware corporation (the “Company”), resigned from his position as Chief Executive Officer of the Company and was succeeded by Roger A. Jeffs, Ph.D.”
Damian deGoa resigned as Director at Liquidia Corp.
“Mr. deGoa’s concurrent resignation as the Company’s Chief Executive Officer”
Roger A. Jeffs, Ph.D. was appointed as Chief Executive Officer at Liquidia Corp.
“Roger A. Jeffs, Ph.D. was appointed by the Board of Directors (the “Board”) of Liquidia Corporation, a Delaware corporation (the “Company”), as the Company’s Chief Executive Officer”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.